Likewise, evidence on the use of IV tissue plasminogen activator (t-PA) in patients with cavernoma is sparse, with 11 individual cases in two case reports15,16 and a single systematic analysis17 that yielded conflicting results. This evidence concerns the gene PLAT and cavernous hemangioma.